ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare ARS Pharmaceuticals to related companies based on the strength of its profitability, dividends, risk, valuation, earnings, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings for ARS Pharmaceuticals and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| ARS Pharmaceuticals Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
ARS Pharmaceuticals currently has a consensus target price of $23.33, suggesting a potential upside of 499.83%. As a group, “Pharmaceuticals” companies have a potential upside of 24.61%. Given ARS Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than its rivals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -163.64% | -453.93% | -71.62% |
| ARS Pharmaceuticals Competitors | -2,398.26% | -203.62% | -15.08% |
Volatility & Risk
ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals’ rivals have a beta of -0.04, meaning that their average share price is 104% less volatile than the S&P 500.
Valuation & Earnings
This table compares ARS Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | -$171.30 million | -1.93 |
| ARS Pharmaceuticals Competitors | $3.55 billion | $3.17 billion | 562.76 |
ARS Pharmaceuticals’ rivals have higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
ARS Pharmaceuticals beats its rivals on 7 of the 12 factors compared.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing needle-free treatments for severe allergic reactions. Its lead product, neffy (epinephrine nasal spray), is designed to provide an alternative to injectable epinephrine for emergency treatment of allergic reactions, including anaphylaxis. The U.S. Food and Drug Administration approved neffy in 2024. The product delivers epinephrine through the nose, addressing the need for a treatment that may be easier to carry and use than an auto-injector.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
